Clinical Trial Update: Pharmacogenetically-guided Escitalopram Treatment for Pediatric Anxiety: Aiming to Improve Safety and Efficacy (PrEcISE) [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating pharmacogenetically-guided escitalopram treatment for pediatric anxiety to improve safety and efficacy; currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anxiety Disorders

Drugs mentioned

• Escitalopram (escitalopram)

Snippet

Sponsor: University of Cincinnati | Conditions: Anxiety | Phase 4 | Status: RECRUITING